Muscle‐directed gene therapy corrects Pompe disease and uncovers species‐specific GAA immunogenicity
Abstract Pompe disease is a severe disorder caused by loss of acid α‐glucosidase (GAA), leading to glycogen accumulation in tissues and neuromuscular and cardiac dysfunction. Enzyme replacement therapy is the only available treatment. AT845 is an adeno‐associated viral vector designed to express hum...
Saved in:
| Main Authors: | Michelle Eggers, Charles H Vannoy, Jianyong Huang, Pravinkumar Purushothaman, Jacqueline Brassard, Carlos Fonck, Hui Meng, Mariah J Prom, Michael W Lawlor, Justine Cunningham, Chanchal Sadhu, Fulvio Mavilio |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2021-12-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.202113968 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Homozygotic intronic GAA mutation in three siblings with late-onset Pompe's disease Mutação homozigótica intrônica no gene GAA em três irmãos com doença de Pompe de início tardio
by: Anderson Kuntz Grzesiuk, et al.
Published: (2010-04-01) -
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease
by: Barry J. Byrne, et al.
Published: (2024-10-01) -
Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease
by: Barry J. Byrne, et al.
Published: (2025-01-01) -
Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism
by: Or Kakhlon, et al.
Published: (2021-09-01) -
Five years of newborn screening for Pompe, Mucopolysaccharidosis type I, Gaucher, and Fabry diseases in Oregon
by: Sarah Viall, et al.
Published: (2025-06-01)